Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sayana Press · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Sayana Press, Upper Arm injection | EXPERIMENTAL | Sayana Press, administered subcutaneously into upper arm |
| Sayana Press, anterior thigh | ACTIVE_COMPARATOR | Sayana Press, administered subcutaneously into anterior thigh |
| Sayana Press, abdomen | ACTIVE_COMPARATOR | Sayana Press, administered subcutaneously into abdomen |
| Name | Type | Description |
|---|---|---|
| Sayana Press | COMBINATION_PRODUCT | Sayana Press is a drug-device combination and is considered a medical product in the EU. |
Inclusion Criteria: * Pre-menopausal female participants, 18 to 45 years of age, inclusive, at the time of signing the ICD who are at low risk of pregnancy * Participants who have a regular menstrual cycle (between 21 and 42 days in length). * No previous injection of depot MPA for 1 year prior to ...
Sayana Press is an investigational small molecule being studied for use in healthy individuals. It is a subcutaneous injection formulation, and the clinical trial focuses on healthy female volunteers. The drug is currently in Phase 1 clinical development.
Sayana Press is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's administration and effects.
Sayana Press is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and pharmacokinetics.
Sayana Press has one completed clinical trial, NCT04893798, which compared subcutaneous injection of Sayana Press in the upper arm versus the anterior thigh and abdomen. The trial enrolled 67 healthy female participants in Belgium and was actively controlled.
Sayana Press is administered as a subcutaneous injection. The completed clinical trial evaluated injection into the upper arm, anterior thigh, and abdomen to compare these administration sites. The study enrolled healthy female volunteers aged 18 years and older.